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Wiskott–Aldrich syndrome protein (WASP) is in a complex with
WASP-interacting protein (WIP).WASP levels, but notmRNA levels,
were severely diminished in T cells from WIP/ mice and were
increased by introduction of WIP in these cells. The WASP binding
domain of WIP was shown to protect WASP from degradation by
calpain in vitro. Treatment with the proteasome inhibitors MG132
and bortezomib increased WASP levels in T cells fromWIP/mice
and in T and B lymphocytes from twoWAS patients with missense
mutations (R86H and T45M) that disrupt WIP binding. The calpain
inhibitor calpeptin increased WASP levels in activated T and B cells
from theWASPpatients, but not in primary T cells from the patients
or from WIP/ mice. Despite its ability to increase WASP levels
proteasome inhibition did not correct the impaired IL-2 gene
expression and low F-actin content in T cells from the R86H WAS
patient. These results demonstrate that WIP stabilizes WASP and
suggest that it may also be important for its function.
proteasome  T cells
WASP, the product of the gene mutated in Wiskott–Aldrichsyndrome (WAS), is expressed only in hematopoietic cells
and is the first identified member of a family of proteins that
include N-WASP and Scar/WAVE (1–3). WASP plays a critical
role in T cell activation and actin reorganization. WASP trans-
locates to lipid rafts after T cell receptor (TCR) ligation and
localizes at the immune synapse between T cells and antigen-
presenting cells (4, 5). T cells from WAS patients and WASP/
mice are deficient in their ability to increase their F-actin
content, secrete IL-2, and proliferate after TCR ligation (6–8).
A complex of WASP/N-WASP andWASP-interacting protein
(WIP) is detected in resting cells (9, 10). WIP is expressed at high
levels in lymphoid tissues (11). NMR studies suggest a narrow
but extended contact between WIP and N-WASP with amino
acid residues 461–485 of WIP wrapping themselves around the
EVH1 domain of N-WASP (12). WIP plays an important role in
the recruitment of the WIP–WASP complex to ZAP-70 after
TCR ligation (5). T cells from WIP knockout mice fail to
proliferate, secrete IL-2, polarize, and extend protrusions after
TCR ligation, are deficient in immune synapse formation, and
have a disorganized actin cytoskeleton (13).
Most missense mutations in patients with WAS and X-linked
thrombocytopenia are localized to the WIP binding EVH1
domain of WASP (12, 14). In fact, three of these mutations,
R86H, Y107C, and A134T, which affect residues that are
predicted by NMR studies to be contact points for WIP, were
shown to disrupt WIP binding (15). Here we demonstrate that
WIP stabilizes WASP from degradation by calpain and the
proteasome.
Results
WASP Is Unstable in the Absence of WIP. Expression of WASP in
splenic T cells from WIP/ mice was severely diminished (Fig.
1A). In contrast, expression of Vav1 and actin was unaffected
(Fig. 1A). Scanning densitometry revealed that the level of
WASP expression in WIP/ T cells was 8.4  0.9% of controls
(n  3). Diminished expression of WASP in WIP/ T cells was
confirmed by intracellular FACS analysis by using anti-WASP
mAb (Fig. 1B). Northern blot analysis revealed similar levels of
WASP mRNA in WIP/ and WT T cells (Fig. 1C). WASP
mRNA levels assessed by quantitative RT-PCR were similar in
WT and WIP/ T cells (mean WASP mRNA level in WIP/
cells, normalized to GAPDH, 90  8% of control T cells, n 
3; data not shown). Examination of B cells from WIP/ mice
revealed severely decreased WASP levels to 10.0  3.0% of
control (n  3) (Fig. 1D). N-WASP level was similar in cultured
lung fibroblasts from WIP/ and WT controls (mean N-WASP
level in WIP/ fibroblasts, normalized to actin, 111  3% of
control fibroblasts) (Fig. 1E). WIP level was not affected by the
absence of WASP (mean WIP level in WASP/ T cells,
normalized to actin level, was 94  2% of control WT T cells,
n 3) (Fig. 1F). These results suggest thatWIP stabilizesWASP.
Overexpression of WIP Results in Increased WASP Levels. Jurkat cells
were stably transfected with myc-tagged constructs that encode
C-terminal WIP (C-WIP, amino acids 401–503) or N-terminal
WIP (N-WIP, amino acids 1–400), placed under the control of
the doxycycline (DOX)-inducible promoter. Myc-tagged C-WIP
but not myc-tagged N-WIP was confirmed to bind WASP (Fig.
2A). DOX treatment of C-WIP-transfected cells, but not of
N-WIP-transfected cells, for 48 h resulted in an3-fold increase
in WASP level (Fig. 2B), with no change in WASP mRNA
expression (data not shown). There was no detectable change in
the level of endogenous WIP in Jurkat cells transfected with
either C-WIP or N-WIP (data not shown). Overexpression of
WIP–GFP in T293 cells caused no detectable increase in N-
WASP levels (Fig. 2C). These results suggest that WIP stabilizes
WASP, but not N-WASP, in cells.
Expression of WIP Increases WASP Levels in WIP/ T Cells. T cells
were transfected by nucleofection with plasmids encoding for
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GFP, WIP–GFP, andWIPWASP–GFP, a deletion mutant that
lacks amino acids 461–488, which are essential for WIP binding
(12). Fig. 3A shows that probing of GFP immunoprecipitates
from transfected cells revealed expression of GFP–WIP fusion
proteins of the appropriate size as detected by anti-GFP anti-
bodies. Fig. 3B shows that WASP was detected in GFP immu-
noprecipitates from WIP–GFP-transfected cells, but not from
WIPWASP–GFP-transfected or GFP-transfected cells. Fig. 3C
shows that expression of WIP–GFP, but not of WIPWASP–
GFP or GFP, in WIP/ T cells resulted in an increase in
WASP levels as determined by FACS. The mean increase
in WASP expression was 2.2 0.3-fold in WIP–GFP-transfected
cells and 0.9 0.1-fold withWIPWASP–GFP transfection (n
3, P  0.05). These results confirm that WIP binding is essential
for WASP stability.
The Majority of WASP and WIP Exist in a Complex in T Cells. To
determine how much of WASP in T cells is associated with WIP
we examined the residual amount of WASP in T cell lysates
immunodepleted of WIP by five sequential immunoprecipita-
tions using WIP mAb. Fig. 4A shows that virtually no WIP could
be detected in the T cell lysates after WIP immunodepletion.
Scanning densitometry revealed that the amount of WASP that
remained in lysates immunodepleted of WIP was 27% and 20%,
respectively, in two independent experiments. Fig. 4B shows that
virtually no WASP could be detected in the T cell lysates after
WASP immunodepletion. Scanning densitometry revealed that
the amount of WIP that remained in lysates immunodepleted of
WASP was, respectively, 12% and 14% in two independent
experiments. Thus, the majority of WASP and WIP are associ-
ated with each other in T cells.
WIP Protects WASP from Degradation by Calpain in Vitro. WASP in
platelet lysates is degraded by the calcium-dependent protease
calpain (16). We first determined whether WASP is a direct
substrate for calpain. In vitro transcribed and translated WASP
was completely degraded by calpain I at 20 units/ml or more but
not by caspase 3 [supporting information (SI) Fig. 7A]. GST-C-
WIP (amino acids 401–503), which binds to WASP, but not
GST-N-WIP (amino acids 1–108), which does not bind toWASP,
inhibited the degradation ofWASP by calpain I (SI Fig. 7B). This
was not because of interference with calpain enzymatic activity,
because GST-C-WIP did not inhibit the degradation of CrkL, a
known substrate of calpain (17) (SI Fig. 7B). These results
suggest that WIP masks calpain-sensitive sites in WASP.
Inhibitors of the Proteasome Increase WASP Levels in WIP/ T Cells.
The finding that WASP is a substrate for calpain and the
observation that N-WASP is subject to ubiquitination (18)
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Fig. 1. WASP is unstable in WIP/ T cells. (A) WASP expression in T cells from
WIP/and WT control mice. Vav and actin protein expression levels are shown
as controls. (B) FACS analysis of intracellular WASP expression in WT, WIP/,
and WASP/ splenic T cells. Cells were stained with anti-WASP mAb 5A5 and
isotype-matched mouse IgG2a as control. (C) Northern blot analysis of WASP
mRNA in splenic T cells from WIP/ mice and WT controls. (D) WASP expres-
sion in B cells from WIP/ and WT controls. (E) N-WASP expression in fibro-
blasts from WIP/ mice and WT controls. (F) WIP expression in T cells from
WASP/ mice and WT controls.
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Fig. 2. Overexpression of WIP in cells results in increased levels of WASP, but
not N-WASP. (A) WASP binding to Myc-tagged N-WIP (1–400) and C-WIP
(401–503) in Jurkat cells transfected with Myc-tagged C-WIP and N-WIP under
the control of a DOX-inducible promoter. The presence of WASP in Myc
immunoprecipitates was examined before and after DOX treatment. To
achieve optimal resolution of Myc-N-WIP (50 kDa) and to avoid Myc-C-WIP
(11 kDa) running off the gel, the gels were run for different time periods. (B)
WASP expression in the same Jurkat cells. Representative results from one of
four independent clones for each construct are shown. The asterisk denotes
nonspecific bands. (C) Forced expression of WIP in T293 cells does not alter
N-WASP levels.
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prompted us to examine whether inhibitors of calpain and/or the
proteasome increase WASP expression in WIP/ T cells. FACS
analysis revealed that preincubation for 6 h of WIP/ T cells
with MG132 increased the level of WASP, but not Vav1 protein
(Fig. 5A). The mean fluorescence intensity for WASP staining in
WIP/ T cells treated with MG132 was 2.2  0.2-fold that of
untreated WIP/ T cells (n  3, P  0.05). The level of WASP
in WIP/ T cells compared with that of untreated WT T cells
rose from 0.10  0.02 to 0.22  0.03 after MG132 treatment as
determined by mean fluorescence intensity (n 3, P 0.05). In
contrast to MG132, calpeptin had no detectable effect onWASP
levels in WIP/ T cells and exerted no additional effect to that
of MG132 when WIP/ T cells were treated with both inhibi-
tors. There was no detectable increase in the level of WASP in
normal T cells treated with MG132 and/or calpeptin (Fig. 5A).
Western blot analysis of T cell lysates confirmed the results
obtained by FACS (Fig. 5B). Densitometric scanning revealed
that the mean WASP levels in WIP/ T cells treated with
MG132 was 2.4 0.2-fold that of untreated WIP/ T cells (n
3, P  0.05). The level of WASP in WIP/ T cells compared
with that of untreatedWTT cells rose from 0.09 0.01 to 0.23
0.04 after MG132 treatment (n 3, P 0.05). Calpeptin had no
detectable effect on WASP levels in WIP/ T cells. Increasing
the concentrations of the inhibitors and/or increasing the incu-
bation time beyond 6 h caused increased cell death and did not
result in a detectable increase in WASP levels. These results
suggest that degradation by the ubiquitin–proteasome pathway
contributes to WASP degradation in the absence of WIP.
We confirmed the above results using additional proteasome
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and calpain inhibitors. Treatment of WIP/ T cells with the
proteasome inhibitor bortezomib caused an increase in WASP
levels comparable to that observed with MG132 (SI Fig. 8A).
This inhibitor caused negligible cell death after 6 h of treatment
but resulted in 90% cell mortality by 24 h. In contrast,
treatment of WIP/ T cells with the calpain inhibitor CS
peptide (27-aa peptide encoded by exon 1B of human calpasta-
tin) caused no detectable increase in WASP levels (SI Fig. 8B).
Both calpeptin and CS peptide were shown to substantially
reduce calpain activity in T cell lysates (SI Fig. 8C).
Effect of Proteasome and Calpain Inhibitors on WASP Levels in
Lymphocytes from WAS Patients with Missense Mutations in WASP
That Disrupt WIP Binding. The majority of WAS patients with
missense mutations in WASP have point mutations in the WIP
binding domain (19). One of these mutations, R86H, was shown
to disrupt WIP binding and to be associated with severely
diminished WASP levels with normal mRNA levels (15). West-
ern blot analysis of lysates from freshly isolated T cells from a
patient with the R86H mutation revealed that the WASP level
in these T cells was 9% that of T cells from healthy controls (n
2 independent experiments using T cells from two healthy
donors as controls in each). Preincubation of freshly isolated T
cells from this patient with MG132 increased WASP levels by a
factor of 2.4-fold (mean of two experiments). This corresponded
to a WASP level 22% that of untreated T cells from normal
controls. There was no detectable effect of calpeptin on WASP
levels in the primary T cells from this patient, with a mean
increase of 0.85-fold in two experiments (Fig. 6A). The combi-
nation of MG132 and calpeptin caused a mean increase of
1.8-fold in WASP levels (n  2) and was associated with
increased cell death. Neither MG132 nor calpeptin caused a
detectable increase in the level of WASP in normal T cells or of
Vav1 in either normal or patient T cells.
T cell activation results in activation of calpain (20–24). We
examined the effect of calpeptin on WASP levels in PHA- and
IL-2-propagated T cell lines derived from the patient with the
R86H mutation and two normal controls. The mean WASP
content of two independent T cell lines from the patient was 12%
that of T cells lines derived from the two normal donors.
Preincubation with MG132 increased WASP levels in the pa-
tient’s cell lines by 2.3 0.4-fold (n 3) to 28% that of untreated
normal T cell lines. Calpeptin treatment of the patient’s T cell
lines caused a 2.1  0.35-fold (n  3) increase in WASP levels
(Fig. 6B). The combination of MG132 and calpeptin caused a
1.8  0.21-fold (n  3) increase in WASP levels and was
associated with increased cell death. This corresponded to a
WASP level 25% that of untreated normal T cell lines. MG132
had no detectable effect on Vav1 levels in the patient’s cell lines.
MG132 and calpeptin had no detectable effect on WASP or
Vav1 levels in normal T cell lines. These results suggest that both
calpain and the proteasome participate in the degradation of the
mutant WASP in activated T cells.
We examined the effect of calpeptin and MG132 on WASP
levels using EBV-transformed B cell lines derived from a WAS
patient with a T45M mutation and two healthy controls. The
T45M mutation is predicted by NMR studies to be a contact
point for WIP binding (12). The patient’s peripheral blood
mononuclear cells and B cell line expressedWASP at a level that
ranged from 15% to 20% that of control but had normal WASP
mRNA levels (25) (Fig. 6C and data not shown). Preincubation
of the patient’s B cell line with MG132 or calpeptin increased
WASP levels by 2.3  0.27-fold and 2.1  0.22-fold, respectively
(mean of three experiments), but had no detectable effect on
Vav1 levels (Fig. 6C). The combination of MG132 and calpeptin
caused a 1.4 0.21-fold (n 3) increase inWASP levels and was
associated with increased cell death. Addition of both inhibitors
resulted in diminished up-regulation of WASP levels compared
with either inhibitor alone and was associated with increased cell
death. MG132 and calpeptin had no detectable effect on WASP
or Vav1 levels in normal B cell lines. These results suggest that
both calpain and the proteasome participate in the degradation
of the mutant WASP in activated B cells.
Effect of the Proteasome Inhibitor Bortezomib on Actin Content and
IL-2 Expression by T Cells with R86H Mutation in WASP. Primary T
cells from patients with WAS have impaired IL-2 gene expres-
sion after stimulation by immobilized anti-CD3 mAb (26), and
herpes virus saimiri-transformed T cell lines from these patients
have a defect in polymerizing actin after TCR ligation (6).
Because the proteasome inhibitor bortezomib was not toxic to
murine T cells in the first 6 h, we examined its ability to correct
the functional defect in primary T cells from the patient with the
R86H mutation in WASP. Bortezomib caused negligible death
of human T cells at 10 h but substantial death (90%) at 24 h.
Incubation of the patient’s T cells with bortezomib for 10 h
resulted in a 2.4 0.5-fold increase in WASP level to 23% of the
level in control T cells (n  3), results similar to those obtained
with MG132. However, bortezomib failed to ameliorate the
impaired IL-2 gene expression in response to immobilized
anti-CD3 mAb (SI Fig. 9A). T cells from the patient had
decreased F-actin content, but, in contrast to what was reported
for herpes virus saimiri-transformed T cell lines from WAS
patients, they were able to polymerize actin after anti-CD3
stimulation. Bortezomib had no effect on the low F-actin content
of these cells (SI Fig. 9B).
Discussion
Our results show that WIP deficiency or impaired WASP–WIP
interaction results in WASP degradation by the proteasome and
calpain. WASP levels were markedly diminished in T cells from
WIP/mice and in lymphocytes of WAS patients with missense
mutations in the EVH1 domain of WASP that disrupt WIP
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binding. The decrease occurred in the face of normal levels of
WASP mRNA (Figs. 1A and 6). In contrast, WIP levels were
normal in WASP-deficient T cells (Fig. 1F), indicating that WIP
is necessary for the stabilization of WASP, but not vice versa.
The finding that N-WASP levels were normal in WIP/ fibro-
blasts (Fig. 1E) suggests that WIP may not be needed to stabilize
N-WASP. This could be because of an intrinsic property of
N-WASP or/and the expression in nonhematopoietic cells of
WIP homologues, such as CR16 and WIRE/WICH (27–29).
Stabilization ofWASP byWIP is likely the result of their direct
interaction rather than an indirect effect of WIP on WASP
degradation. First, overexpression of a WIP fragment that binds
WASP, but not of a WIP fragment that does not bind WASP,
increased WASP expression in Jurkat cells (Fig. 2). Second,
expression of WIP, but not of a WIP deletion mutant that does
bind WASP, resulted in an increase in WASP levels in WIP/
T cells (Fig. 3). Third, a WIP fragment that binds WASP, but not
a WIP fragment that does not bind WASP, protected WASP
from degradation by calpain in vitro (SI Fig. 7). Finally, WASP
levels are decreased in lymphocytes from patients with point
mutations that destroy WIP binding (Fig. 6). We were unable to
detect WASP fragments in WIP/ T cells or in lymphocytes
from WAS patients with the R86H and T45M mutations. This is
possibly because of rapid degradation of these fragments.
Preincubation with the proteasome inhibitor MG132, but not
with the calpain inhibitor calpeptin, partially restored WASP
levels in primary T cells from WIP/ mice and from a WAS
patient with a missense mutation in the EVH1 domain ofWASP,
R86H, that disruptsWIP binding (Figs. 5 and 6A). Similar results
were obtained in WIP/ T cells with the proteasome inhibitor
bortezomib and the calpain inhibitor CS peptide (SI Fig. 8). This
suggests that WIP is a chaperone for WASP and that, in its
absence, WASP can be degraded in primary T cells by the
ubiquitin–proteasome pathway. The increase in WASP levels
was specific because it was not observed in normal T cells and
because Vav1 levels were unaffected. The failure to observe a
detectable effect of MG132 on WASP levels in normal T cells
may be explained by the observation that the majority of WASP
is complexed with WIP in T cells (Fig. 4).
Our findings implicate calpain inWASP degradation in activated
lymphocytes of patients with WASP mutations that disrupt WIP
binding. In contrast to primary T cells, calpain inhibition increased
WASP levels in activated T cells of the R86H patients and in
EBV-transformed cells from anotherWAS patient with a missense
mutation, T45M, that disrupts WIP binding (Fig. 6 B and C).
Calpain is known to be activated after TCR and B cell receptor
cross-linking (22, 30). Furthermore, calpain mRNA and expression
levels are increased after activation of T and B cells (31).
WASP has seven potential calpain-sensitive sites based on the
highly stringent criterion of P1 residue being Y, M, or R and P2
residue being a hydrophobic amino acid (32). Four of these sites are
in the EVH1 domain. Using less stringent criteria, there are several
additional potential calpain-sensitive sites in WASP. Our finding
that the C-terminal WASP binding domain of WIP specifically
protected WASP from degradation by calpain (SI Fig. 7) suggests
that calpain attacks sites in the EVH1 domain of WASP and that
WIPmasks these sites. TheminimalWIP peptide that bindsWASP
spans amino acids 461–485. We found that this peptide does not
protect WASP from degradation by calpain in vitro (data not
shown), suggesting that other regions ofWIP contribute to its ability
to protect WASP from degradation.
There are many similarities in the phenotype of WAS knock-
out mice and WIP knockout mice. They include defective
proliferation and IL-2 secretion in response to immobilized
anti-CD3 and defective immune synapse formation and F-actin
reorganization (8, 13, 33). The finding that WASP levels are
severely diminished in T cells from WIP/ mice suggests that
WASP deficiency contributes to the phenotype of these mice.
However, WIP/ T cells, but not WASP/ T cells, have a
disrupted subcortical actin cytoskeleton (13) and show severe
defects in chemotaxis in response to stromal cell-derived factor
1 (34). Furthermore, the phenotype of WIP and WASP double
deficient mice is markedly more severe than that of either WIP
or WASP single deficient mice, with reduced numbers of thy-
mocytes and peripheral CD4 T cells and early development of
colitis, pneumonitis, and iritis (our unpublished observations).
These observations strongly suggest that WIP, which interacts
independent of WASP with a number of proteins that include
Nck, CrkL, Syk, actin, and profilin (5, 11, 35, 36), has distinct
functions, which are not dependent on WASP.
We were unable to observe amelioration of the impaired IL-2
gene expression in response to immobilized anti-CD3 and of the
decreased F-actin content of T cells with R86H mutation in
WASP after incubation with bortezomib for 10 h, a time at which
cell viability was intact (SI Fig. 9). It is possible that the WASP
levels achieved may have not been sufficient to correct these
defects. Alternatively, the ability of WASP to correct these
defects may depended on its capacity to interact and function
with WIP as a complex. A genetic approach in which a minimal
WIP fragment that is sufficient to normalize WASP level is
expressed in WIP/ T cells is needed to distinguish between
these possibilities.
Experimental Procedures
Cells, Mice, Reagents, and Antibodies. Jurkat E6–1 T cells were
obtained fromAmerican Type Culture Collection (Manassas, VA).
Generation and characterization of WIP/ and WASP/ mice
have been reported previously (8, 13). Mouse thymocytes were
purified as described previously (13). Blood was obtained from
WAS patients and controls with informed consent, and T cells were
purified from peripheral bloodmononuclear cells by using a human
Magcellect Cell isolation kit (R & D Systems, Minneapolis, MN).
T cell lines were derived by stimulation with PHA (10 g/ml) for 3
days, and after 3 days the cells were expanded by addition of 100
units/ml human rIL-2 (R & D Systems). EBV-transformed B cell
lines were established by using a standard protocol. Cells were
cultured in RPMImedium 1640 with 10%FCS.WIP/ fibroblasts
derived from lung were cultured in Iscove’s modified Dulbecco’s
medium with 10% FCS (13).
MG132, calpain I, calpeptin, caspase inhibitor Z-VAD-FMK,
and human calpastatin exon 1B encoded peptide (CS peptide)
were purchased from Calbiochem (San Diego, CA). Bortezomib
(Velcade) was obtained from Millennium Pharmaceuticals
(Cambridge, MA). FuGene transfection agent was from Roche
(Indianapolis, IN). Generation of rabbit anti-WIP antiserum
C14, anti-WASP antiserum K-374, and anti-WASP mAb 5A5
was described previously (5, 6, 37). Anti-WASP mAb B-9,
anti-Vav, anti-CrkL mAb, and rabbit anti-NWASP antibody
(H-100) were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-actin mAb was purchased fromChemicon (Temecula, CA).
Anti-Vav1 was purchased from Abcam (Cambridge, MA). Anti-
c-myc mAb 9E10 was from the Developmental Studies Hybrid-
oma Bank at the University of Iowa (Iowa City, IA). Anti-WIP
mAb 3D10 was raised against the N terminus of WIP. Calpain
inhibition was quantified by using a calpain assay kit (Biovision,
Mountain View, CA) as suggested by the manufacturer except
that the cell lysates were incubated with the substrate overnight,
protected from light.
Transfection of T Cells with WIP–GFP and GFP–WASP Constructs.WT
WIP and WIP -461–488 were cloned in phase with GFP at the
C terminus of WIP in the expression vector pCDNA3. Five
micrograms of each construct was used to transfect 1 	 107 T
cells by using a mouse T cell nucleofector kit and an Amaxa
Biosystem nucleofector. The program X-01 was used, and opti-
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mal expression of the fusion proteins was observed 18 h after
transfection.
For the analysis of WASP expression level, transfected cells
were permeabilized and stained with mAb 5A5 or mAb B-9 by
using goat anti-mouse phycoerythrin (BD Biosciences, San Jose,
CA) as the second antibody. WASP fluorescence in gated GFP
cells was analyzed by FACS. In parallel, 1	 107 transfected cells
were lysed in lysis buffer [50 mM Tris, pH 7.4/100 mM NaCl/1%
Triton X-100/protease inhibitors (Complete, Roche)], immuno-
precipitated with anti-GFP polyclonal antibody (BD Bio-
sciences), Western blotted, and probed with anti-WASP mAb
B-9. The blots were stripped and reprobed with anti-GFP mAb
(BD Biosciences).
Stable Transfection and Inducible Expression of WIP. Human N-
terminal WIP (1–400) and C-terminal WIP (401–503) were
cloned in frame into pTRE2hyg2-myc vector (Clontech, Moun-
tain View, CA) and sequence-verified. A total of 10 g of
plasmids was transfected by electroporation into 1 	 107 Jurkat
cell clones stably transfected with pTet-on vector (Clontech) by
using a Bio-Rad Genepulser II set at 250 V and 975 F. Cells
were selected with 150 g/ml hygromycin B (BD Biosciences)
and 300 g/ml G418 (Calbiochem) for 21 days. Selected cells
were subjected to limiting dilution, each clone was cultured in the
absence or presence of 2 g/ml DOX (Clontech) for 48 h, and
the cell lysates were analyzed by immunoblotting.
Cell Stimulation, Immunoprecipitation, Immunoblotting, and North-
ern Blotting. Cells were lysed in ice-cold lysis buffer containing
1% Triton X-100, and lysates were clarified at 16,000 	 g for 15
min at 4°C and precleared for 1 h with protein G-Sepharose
(Amersham Pharmacia Biotech, Fairfield, CT). Immunoprecipi-
tation was performed overnight at 4°C with the indicated
antibody (4 g) or antiserum (4 l) preadsorbed onto protein
G-Sepharose. Beads were washed five times with modified lysis
buffer containing 0.2% Triton X-100. Bound proteins were
eluted, run on SDS/PAGE 4–15% gradient gels, and analyzed by
Western blotting with indicated antibodies followed by goat
anti-mouse or anti-rabbit antibodies conjugated to HRP and
ECL detection (PerkinElmer, Boston, MA) as previously de-
scribed (5). Densitometry was performed by using NIH Image
version 1.63 software. WASP:Vav1 ratios were calculated and
normalized to the ratio of medium-treated cells, which was given
a value of 1. Northern blotting and probing for murine WASP
mRNA were performed as described previously (8).
Protein Preparation and in Vitro Calpain Cleavage. Linearized hu-
man WASP cDNA (1 g) was transcribed and translated in vitro
with 50 l of TNT-coupled reticulocyte lysate system (Promega,
Madison, WI). GST-CrkL, GST-C-WIP (401–503), and GST
protein were purified as described previously (5). In vitro trans-
lated WASP or GST-CrkL (25 ng) was preincubated with 40
ng of GST-WIP or GST alone for 1 h on ice. In vitro cleavage
assay with calpain was performed by incubating WASP at the
indicated concentrations of calpain I in reaction buffer contain-
ing 100 mM imidazole (pH 7.4), 10 mM 2-mercaptoethanol, and
5 mM CaCl2 with or without 100 M calpeptin or 5 mM EDTA
for 10 min at 30°C. Cleavage assay with caspase-3 was performed
by incubating the same substrates at the indicated concentrations
of caspase-3 in a reaction buffer containing 50 mM Hepes (pH
7.4), 100 mM NaCl, 0.1% CHAPS, 10% glycerol, and 10 mM
DTT with or without 50 MZ-DEVD-FMK for 30 min at 30°C.
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